Ticker | Company Name | Drug Name | Indication | NCT | Next Catalyst | Stage | FDA Status | Catalyst Date | Conference | Market Cap | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
T TECX | Tectonic Therapeutic Inc. | RXFP1 Agonist (TX45 – Fc-relaxin) | Heart Failure with Preserved Ejection Fraction (HFpEF) | Full Results | Phase 1b | Ongoing | 2026-12-31 | $564.6M | $434.7K | ||
T TECX | Tectonic Therapeutic Inc. | RXFP1 Agonist (TX45 – Fc-relaxin) | Heart Failure with Preserved Ejection Fraction (HFpEF) | Initial Data | Phase 2 | Enrollment Initiation | 2026-12-31 | $564.6M | $434.7K | ||
A ACTU | Actuate Therapeutics Inc. | Elraglusib in Combination with FOLFIRINOX and Losartan | Previously Untreated Metastatic Pancreatic Cancer | NCT05077800 | Phase 2 | Enrollment Conclusion | 2026-12-31 | $51.4M | $193.3K | ||
K KNSA | Kiniksa Pharmaceuticals Ltd. | KPL-387 | Recurrent pericarditis | NCT07010159 | Initial Data | Phase 2/3 | Ongoing | 2026-12-31 | $6.1B | $361.4K | |
R RCUS | Arcus Biosciences Inc. | Quemliclustat, domvanalimab, zimberelimab, and chemotherapy (ARC-21) - (STAR-221) | Locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma | NCT05568095 | Interim Data | Phase 3 | Enrollment Conclusion | 2026-12-31 | $2.5B | $1.1M | |
G GILD | Gilead Sciences Inc. | Quemliclustat, domvanalimab, zimberelimab, and chemotherapy (ARC-21) - (STAR-221) | Locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma | NCT05568095 | Interim Data | Phase 3 | Enrollment Conclusion | 2026-12-31 | $171.5B | $15.8M | |
N NVCR | NovoCure Limited | Tumor Treating Fields (TTFields) - (PANOVA-4) | Metastatic pancreatic cancer | Initial Data | Phase 2 | Ongoing | 2026-12-31 | $1.3B | $1.0M | ||
C CBIO | Crescent Biopharma Inc. | CR-001 | NSCLC, other solid tumors | Phase 1 | Ongoing | 2026-12-31 | $317.9M | $115.5K | |||
B BMY | Bristol-Myers Squibb Company | RYZ101 - (ACTION-1) | Gastroenteropancreatic neuroendocrine tumors | NCT05477576 | Full Results | Phase 1b | Data Released | 2026-12-31 | $116.9B | $14.0M | |
S SHPH | Shuttle Pharmaceuticals Holdings Inc. | Ropidoxuridine | Glioblastoma | NCT06359379 | Initial Data | Phase 2 | Ongoing | 2026-12-31 | $5.2M | $79.3K |
Rows per page
Page 1 of 19